Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Life Sciences Hires Continue to Explode, Goodwin Latest to Add Partner (Law.com)

Related Content

DEA Proposes Rules to Allow Prescribing Controlled Substances via Telemedicine, Subject to Significant Limitations

R&W Insurance Coverage for Healthcare Services Transactions

DOJ Revises Corporate Compliance Guidance to Take on Compensation Incentives and Communications Preservation — With a Continued Emphasis on Individual Accountability

Texas Sues to Challenge Federal Guidance Asserting that Refusal to Fill Prescriptions for Certain Drugs Used to Manage Reproductive Health and Other Conditions May Violate Anti-Discrimination Laws

DOJ Announces Nationwide Voluntary Corporate Self-Disclosure Policy in Effort to Standardize and Incentivize Timely Self-Reporting

CMS Issues Proposed Guidance on Inflation Rebates Under Medicare Part B

CMS Issues Proposed Guidance on Inflation Rebates Under Medicare Part D

Antitrust & Competition Healthcare Quarterly Update Q4 2022

Goodwin named in Top 3 for US Private Equity Debt Deals in 2022

Benchmark Litigation US Awards Name Goodwin Massachusetts Firm of the Year

Abortion Pill Ruling Looms Over FDA's Drug Approval Process (Axios)

Abortion Pill Court Docket Delay Concerns Legal Advocates (Bloomberg Law)

BridgeBio Pharma Announces Pricing of Public Offering of Common Stock

Cano Health Closes $150 Million Term Loan Facility in February 2023 with Diameter Capital Partners and Rubicon Founders

FTC Takes 'Shot Across the Bow' on Health Data, Attorneys Say (Axios)

Abortion Pill, Vaccine Attacks Spell Trouble for FDA Approvals (Bloomberg Law)

Healthcare

Life Sciences